Author(s)

Nahla Ali Mobark^1*, Suha A. Tashkandi², Wafa Al Shakweer³, Khalid Al Saidi², Suha A. Fataftah², Mohammed M. Al Nemer¹, Awatif Alanazi¹, Mohammed Rayis¹, Walid Ballourah¹, Othman Mosleh¹, Zaheer Ullah¹, Fahad El Manjomi¹, Musa Al Harbi¹

¹Department of Pediatric Hematology and Oncology, Comprehensive Cancer Centre, KFMC, Riyadh, Saudi Arabia.
²Department of Cytogenetic and Molecular Cytogenetic Laboratory, KFMC, Riyadh, Saudi Arabia.
³Department of Anatomical Pathology, KFMC, Riyadh, Saudi Arabia.

Background: Non-Hodgkin’s lymphoma is an aggressive malignant disease in children and adolescents. Although it is the fourth most common malignancy in Saudi children as reported in Saudi cancer registry, less information is available about pediatric Non-Hodgkin lymphoma and its outcome in Saudi Arabia. Study Objectives: To provide demographic data, disease characteristics, treatment protocol, toxicity and outcome of treatment in children & adolescents with Non-Hodgkin’s lymphoma treated at KFMC. This study will form base line for future studies about pediatric Non-Hodgkin’s lymphoma in KFMC, which may help to improve outcome for children with cancer in Saudi Arabia. Study Patients and Method: We retrospectively analyzed 28 children and adolescents diagnosed to have Non-Hodgkin’s lymphoma at KFMC between December 2006 and December 2013, followed-up through June 2014. Results: Of the 28 patients, 10 (35.7%) girls and 18 (64.3%) boys, the male-to-female ratio was 1.8; 1. The median age at time of diagnosis was 6.4 years old (range 2.0 to 13.0 years old). The majority of patients (64.3%) were aged between 5 and 12 years old. Burkitt’s lymphoma BL/BLL was the most common pathological subtype (60.7%), and DLBCL was the second most common subtype (21.4%). Abdominal and Retroperitoneal involvement was the most common primary site (78.6%) including the ileocaecal region. Most of the children presented with advanced Stage III and IV (75%), Cytogenetic study which screens specifically for the t (8; 14) (q24; q32) a characteristic genetic feature of Burkitt’s Lymphoma was obtained from 21 patients, variant rearrangement was observed in 3/21 samples and complex chromosomes karyotype in addition to IGH/MYC rearrangement was observed in 2/21 samples. Those patients presented with very aggressive lymphoma and combined BM and CNS involvement. We use the French-American-British Mature B-Cell Lymphoma 96 Protocol (FAB LMB 96) for treatment fornewly diagnosed Mature B-Cell type NHL and high risk ALL CCG 1961 Protocol for lymphoblastic lymphoma and international Anaplastic Large Cell Lymphoma 99 Study Protocol for ALCL. The median follow-up in patients not experiencing an adverse event was 53.1 months. The estimated 3-year EFE and OS rates in the entire cohort of patients with newly diagnosed NHL treated in the KFMC were 85.2% and 89.2% respectively; Overall survival (OS) rate of patients with mature B-cell-NHL was 88.9%. Conclusion: The outcomes and survival in our small series appeared to be excellent compared with those reported in other international trials even though most of our patients presented in advanced stage of the disease. We feel that the importance of the current study is to document the relative distribution of various types of pediatric non-Hodgkin’s lymphomas and age-specific distribution in different Histological subtypes.

Non-Hodgkin Lymphoma, Disease, Patients, Children and Adolescents

Mobark, N. , Tashkandi, S. , Shakweer, W. , Saidi, K. , Fataftah, S. , Nemer, M. , Alanazi, A. , Rayis, M. , Ballourah, W. , Mosleh, O. , Ullah, Z. , Manjomi, F. and Harbi, M. (2015) Pediatric Non-Hodgkin Lymphoma: A Retrospective 7-Year Experience in Children & Adolescents with Non-Hodgkin Lymphoma Treated in King Fahad Medical City (KFMC). Journal of Cancer Therapy, 6, 299-314. doi: 10.4236/jct.2015.64033.